Want to see SE:LARK full AI Analyst Report?
Top Page
CombiGene AB
(LARK)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr2.00
▼(-14.89% Downside)
Action:Reiterated
Date:07/01/26
The score is held down primarily by very weak financial performance (revenue collapse, sustained losses, and ongoing cash burn), partially offset by a debt-free balance sheet with remaining equity. Technicals are broadly neutral with price near key moving averages, while valuation signals are mixed due to a negative P/E and an unusually high stated dividend yield.
Positive Factors
Debt-free balance sheet
A lack of reported debt and a still-positive equity base materially lowers near-term default risk and preserves strategic optionality. For a loss-making biotech, this balance-sheet structure lengthens runway for R&D and clinical programs without immediate refinancing pressure, supporting program continuity over months.
Negative Factors
Revenue collapsed to near zero
Revenue falling to essentially zero eliminates any operational self-funding and prevents leveraging fixed-cost investments. Over a multi-month horizon this forces reliance on external funding or asset sales, increasing execution risk and making it harder to sustain R&D programs without dilutive or conditional financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A lack of reported debt and a still-positive equity base materially lowers near-term default risk and preserves strategic optionality. For a loss-making biotech, this balance-sheet structure lengthens runway for R&D and clinical programs without immediate refinancing pressure, supporting program continuity over months.
Read all positive factors
CombiGene AB (LARK) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr44.35M
Dividend Yield8.47%
Average Volume (3M)41.41K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees1
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-1.78
Shares Outstanding19,801,197
10 Day Avg. Volume70,026
30 Day Avg. Volume41,406
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.81
Price to Sales (P/S)0.00
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CombiGene AB Business Overview & Revenue Model
Company Description
Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet...
How the Company Makes Money
null...
CombiGene AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.52M | 0.00 | 326.00K | 5.54M | 26.70M | 84.04M |
| Gross Profit | -15.15M | -8.16M | -46.78M | -21.29M | -19.20M | 15.16M |
| EBITDA | -23.75M | -12.28M | -34.22M | -35.98M | -5.86M | 23.56M |
| Net Income | -35.45M | -12.36M | -44.88M | -35.66M | -6.16M | 20.96M |
Balance Sheet | ||||||
| Total Assets | 61.19M | 56.73M | 75.88M | 120.61M | 158.22M | 166.22M |
| Cash, Cash Equivalents and Short-Term Investments | 60.28M | 5.84M | 73.75M | 101.44M | 131.78M | 136.74M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.91M | 1.24M | 4.30M | 4.16M | 6.10M | 7.94M |
| Stockholders Equity | 55.28M | 55.49M | 71.58M | 116.46M | 152.12M | 158.28M |
Cash Flow | ||||||
| Free Cash Flow | -21.66M | -12.78M | -29.95M | -30.67M | -16.67M | 21.97M |
| Operating Cash Flow | -21.66M | -12.78M | -29.95M | -30.56M | -16.67M | 22.11M |
| Investing Cash Flow | -81.00K | -49.78M | -81.00K | -988.90K | 0.00 | -147.73K |
| Financing Cash Flow | -3.96M | -3.96M | 0.00 | 0.00 | 0.00 | 65.88M |
CombiGene AB Technical Analysis
Negative
2.35
Price Trends
2.27
Negative
2.21
Positive
2.30
Negative
Market Momentum
>-0.01
Positive
45.65
Neutral
42.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Negative. The current price of 2.35 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 2.27, and above the 200-day MA of 2.30, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 42.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LARK.
CombiGene AB Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr429.45M | 5.16 | -264.12% | ― | 147.35% | ― | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
54 Neutral | kr63.81M | -21.20 | -30.39% | 11.26% | ― | 84.53% | |
46 Neutral | kr44.35M | -1.74 | ― | 8.47% | ― | ― | |
42 Neutral | kr36.27M | -0.15 | -88.65% | ― | -1.72% | 17.86% |
* Financial Sector Average
SE:LARK
CombiGene AB
2.24
-0.16
-6.67%
SE:2CUREX
2cureX AB
2.00
-1.63
-44.90%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
1.55
-8.09
-83.93%
SE:SPRINT
Sprint Bioscience AB
4.07
3.57
710.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.